

**FOOD AND DRUG ADMINISTRATION (FDA)**  
Center for Drug Evaluation and Research (CDER)

*Dermatologic and Ophthalmic Drugs Advisory Committee Meeting*

HILTON WASHINGTON DC / SILVER SPRING  
SILVER SPRING, MARYLAND

JUNE 18, 2008

**AGENDA**

The committee will discuss supplemental biologic licensing application (sBLA) 103795/5350, etanercept, a lyophilized powder for subcutaneous injection, Immunex Corp., proposed for the treatment of moderate to severe psoriasis in the pediatric population.

---

8:00 a.m. Call to Order and Opening Remarks

Introduction of Committee

8:15 a.m. Conflict of Interest Statement  
FDA Introductory Remarks

**OPEN PUBLIC HEARING**

**INDUSTRY PRESENTATION**

Questions to Presenters

**FDA PRESENTATION**

Questions to Presenters

12:00 a.m. Questions to the DODAC and Discussion

2:00 p.m. **ADJOURN**